No Data
Express News | Creative Medical Technology Holdings, Inc. Advances FDA Cleared Adapt Clinical Trial With Positive Independent Review, Validating the Safety and Potential of Celz-201 for Chronic Lower Back Pain Treatment
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial With Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 Loss per Share (Vs US$1.02 Loss in 3Q 2023)
Creative Medical Technology | 10-Q: Q3 2024 Earnings Report
Creative Medical Technology Files to Sell 837,104 Shares of Common for Holders
Express News | Creative Medical Technology Files Patent For "AI Enhanced Real-Time Biological Optimization And Health Monitoring For Space Travel"
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
